Compare VSEC & AMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VSEC | AMRX |
|---|---|---|
| Founded | 1959 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | 6.2B |
| IPO Year | 1995 | 2018 |
| Metric | VSEC | AMRX |
|---|---|---|
| Price | $215.40 | $17.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | ★ $226.29 | $15.60 |
| AVG Volume (30 Days) | 346.4K | ★ 1.7M |
| Earning Date | 05-05-2026 | 05-01-2026 |
| Dividend Yield | ★ 0.25% | N/A |
| EPS Growth | N/A | ★ 157.89 |
| EPS | ★ 1.94 | 0.37 |
| Revenue | ★ $760,113,000.00 | N/A |
| Revenue This Year | $32.16 | $4.48 |
| Revenue Next Year | $21.36 | $7.13 |
| P/E Ratio | $113.92 | ★ $48.68 |
| Revenue Growth | ★ 9.88 | N/A |
| 52 Week Low | $154.74 | $9.32 |
| 52 Week High | $247.85 | $19.26 |
| Indicator | VSEC | AMRX |
|---|---|---|
| Relative Strength Index (RSI) | 49.06 | 47.96 |
| Support Level | $163.30 | $16.61 |
| Resistance Level | $229.74 | $18.13 |
| Average True Range (ATR) | 9.82 | 0.58 |
| MACD | -1.89 | -0.07 |
| Stochastic Oscillator | 15.54 | 46.73 |
VSE Corp is a diversified aftermarket products and services company serving commercial and government markets. The Company's operations include aircraft and airframe parts supply and distribution, and MRO services of aircraft components and engine accessories. The Company operates as a single reportable segment: Aviation, which is a provider of aftermarket parts distribution and MRO services for components and engine accessories supporting commercial, business, and general aviation operators.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.